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Abstract 
Based on the principle that immune ablation followed by HSC-mediated recovery purges 
disease-causing leukocytes to interrupt autoimmune disease progression, hematopoietic stem cell 
transplantation (HSCT) has been increasingly used as a treatment for severe autoimmune diseases.  
Despite clinically-relevant outcomes, HSCT is associated with serious iatrogenic risks and is 
suitable only for the most serious and intractable diseases.  A further limitation of autologous 
HSCT is that relapse rates can be high, suggesting disease-causing leukocytes are incompletely 
purged or the environmental and genetic determinants that drive disease remain active.  
Incorporation of antigen-specific tolerance approaches that synergise with autologous HSCT could 
reduce or prevent relapse.  Further, by reducing the requirement for highly toxic immune-ablation 
and instead relying on antigen-specific tolerance, the clinical utility of HSCT could be 
significantly diversified.  Substantial progress has been made exploring HSCT-mediated induction 
of antigen-specific tolerance in animal models but studies have focussed on primarily on 
prevention of autoimmune diseases.  However, as diagnosis of autoimmune disease is often not 
made until autoimmune disease is well developed and populations of autoantigen-specific 
pathogenic effector and memory T cells have become well established, immunotherapies must be 
developed to address effector and memory T-cell responses which have traditionally been 
considered the key impediment to immunotherapy.  Here, focusing on T-cell mediated 
autoimmune diseases we review progress made in antigen-specific immunotherapy using HSCT-
mediated approaches, induction of tolerance in effector and memory T cells and the challenges for 
progression and clinical application of antigen-specific ‘tolerogenic’ HSCT therapy.    
 
Key Words: autoimmune disease, tolerance, haematopoietic stem cell transplantation, gene 
therapy  
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1. Autoimmune Disease 
Autoimmune diseases afflict approximately 5-8% of the world’s population [1] and are 
generally categorized as systemic or organ-specific.  In systemic autoimmune diseases pathogenic 
effects are widely disseminated, affecting a range of target organs or tissues.  Pathogenesis is 
complex but can often involve antibody-mediated target organ damage such as that mediated by 
anti-nuclear antibodies in systemic sclerosis and systemic lupus erythematosus (SLE).  Organ-
specific autoimmune diseases, on the other hand, typically result from T-cell-mediated 
autoimmune processes where CD4
+
 and/or CD8
+
 T-cell responses are directed against an often 
limited number of antigens expressed within specific tissues.  This results in damage generally 
confined to specific target organs or tissues.  Classic examples of organ-specific autoimmune 
diseases are Type 1 Diabetes (T1D), multiple sclerosis (MS), Graves’ disease, autoimmune 
gastritis, and Addison’s disease.  In these diseases, proteins expressed by pancreatic beta cells, 
myelinated oligodendrocytes, thyroid exocrine, gastric paracrine cells or adrenal glands 
respectively are targeted.  Because of the unique functions of the target tissues attacked, organ-
specific autoimmune diseases are particularly debilitating and can be life-threatening.  For 
example, destruction of the insulin-secreting islet beta cells in T1D is fatal without exogenous 
insulin replacement.  Demyelination and scarring of axons in MS leads to progressive paralysis, 
loss of thyroid hormone-producing cells in thyroiditis to metabolic disorders and destruction of 
gastric parietal cells in autoimmune gastritis to an inability to absorb vitamin B12 resulting in 
pernicious anaemia.  While T cells drive pathogenesis, other leukocytes including macrophages 
have been implicated as key mediators of target tissue destruction [2].   
 
2. Failure of immunological tolerance underlies autoimmune disease 
Immunological tolerance is essential for immune homeostasis and controls responses to self-
antigens and innocuous environmental antigens while permitting appropriate responses to 
pathogens.  Such is the importance of immune tolerance that several mechanisms have co-evolved.  
Central tolerance occurs in the thymus and bone marrow, respectively, for T cells and B cells.  In 
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the thymus, developing thymocytes undergo a series of ‘testing’ processes including selection on 
the basis of effective recognition of self-Major Histocompatibility Complex (MHC) (positive 
selection) and TCR affinity with self-MHC/antigen (negative selection).  Thymocytes with high 
affinity for ‘self’ (potentially pathogenic) are deleted, a proportion of cells of intermediate affinity 
are recruited into the CD4
+
CD25
+
FoxP3
+
 regulatory T cell (Treg) pool and those with minimal 
self-reactivity exit into the peripheral naive T cell pool.  However, negative selection is not 
absolute and T cells with specificity for autoantigens frequently escape the thymus.  A series of 
secondary, fail-safe, peripheral tolerance processes exist which control autoreactive T cells that 
escape central tolerance.  Peripheral tolerance is comprised of ‘dominant’ mechanisms mediated 
by, for example, Treg that limit the function of T-cells and other leukocytes [3], or ‘recessive’ 
processes that cell-intrinsically limit function T-cell function.  Autoreactive T-cells encountering 
antigen-presenting cells (APC) presenting cognate antigen in the periphery or in secondary 
lymphoid tissues in the absence of inflammation are induced to die (deletion) or are rendered 
unresponsive (anergic) [4].  The importance of such ‘recessive’ peripheral tolerance mechanisms 
has been highlighted in studies showing that autoreactive T cells are commonly found in healthy 
individuals [5, 6].  In particular, dendritic cells play a key role in mediating peripheral tolerance 
and have been identified as ideal tools for induction of tolerance in transplantation and 
autoimmune disease [7, 8] .   
 
Interaction of genetic determinants and environmental influences can lead to tolerance 
breakdown and development of destructive autoreactive T-cell or B-cell responses in susceptible 
individuals.  Genetic determinants of disease susceptibility have been long investigated and recent 
GWAS studies are proving a powerful tool for defining implicated immunological pathways.  
MHC alleles are major risk determinants for systemic and organ-specific autoimmune diseases.  
For example, 50% of the genetic susceptibility underlying T1D [9] is determined by the presence 
of a ‘susceptible’ MHC haplotype and MHC haplotype is an important determinant in other 
autoimmune diseases including MS and RA [10, 11].  Non-MHC genes also contribute to the 
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genetic autoimmune diseases risk with single nucleotide polymorphisms (SNP) in CTLA-4, 
PTPN22 and IL-2 genes, for example, implicated as contributory factors to several prominent 
autoimmune diseases. CTLA-4 polymorphisms have been associated with T1D , MS , SLE  and 
RA and recent evidence suggests a potential role for IL-2 in susceptibility to SLE and T1D. The 
contribution of these genetic determinants to autoimmune disease susceptibility can be readily 
explained mechanistically by their impact on pathways of central or peripheral tolerance.  For 
example, CTLA-4 is a negative regulator of T cell function that binds to co-stimulatory molecules 
and has a central role in maintaining peripheral tolerance [12].  PTPN22 encodes the protein 
tyrosine phosphatase non-receptor type 22 that modulates T cell receptor signalling [13] and is 
crucial in setting the threshold for thymic negative selection. IL-2 is a T-cell cytokine crucial for 
survival and function of CD4
+
CD25
+
FoxP3
+
 regulatory T cells and perturbations of IL-2 
homeostasis mediated through, for example, reduced production contribute to SLE and T1D [14, 
15].  Some immunotherapeutic approaches may be able to bypass genetic ‘deficiencies’ such as 
these by strengthening alternate tolerance pathways  
 
Although genetic influences underlying autoimmune disease are being elucidated, it is the 
interaction between environmental influences and genetic susceptibility that controls disease 
emergence.  The importance of environmental influences is evidenced by the massive surge in 
autoimmune disease incidence that has occurred over the last 70 years, far too fast to be explained 
by changing genetic influences [16]. Pinpointing environmental factors that influence the 
development of autoimmune disease has proven difficult, although infection and dietary triggers 
are the current frontrunners.  For example, molecular mimicry has been implicated in T1D since 
the discovery of a shared determinant between the Coxsackie B virus P2-C protein and GAD65 
[17] and a role for Epstein Barr virus in MS has also been proposed [18].  Changes in lifestyle and 
environmental exposures associated with the development of the’ modern’ lifestyle appear to be 
an important driver of autoimmune disease.  Although direct evidence supporting a role for most 
environmental influences in autoimmune disease development is lacking, the influence of smoking 
Coleman et al., Induction of antigen-specific tolerance ...  6 
 
on RA development through generation of citrinullated antigens is perhaps the most convincing 
[19] and smoking has also being implicated in MS and SLE [20, 21].  In a similar manner to 
genetic determinants, targeting tolerance pathways may be an important approach to overcoming 
environmental influences that drive autoimmune disease in susceptible individuals.  
 
3. Current treatments for autoimmune disease 
Immunosuppressive drugs are prescribed to treat many autoimmune diseases in an attempt to 
dampen the immune response.  However, blanket immunosuppression is accompanied by a host of 
negative side effects, including increased susceptibility to serious infection and risk of 
malignancy.  Recently, monoclonal antibodies and other ‘biologics’ have shown great promise for 
treatment of autoimmune diseases and offer a more specific, though not entirely targeted, 
approach than blanket immunosuppression.  For example, blockade of TNF-α signalling with the 
antibodies infliximab and adalimumab or the decoy receptor etanercept are commonly used to 
treat rheumatoid arthritis and Crohn’s disease while the anti-CD20 antibody rituximab has also 
recently been used to treat rheumatoid arthritis and shows promise in T1D.  These approaches, 
although refined, are still associated with unwanted side-effects and do not specifically target 
disease-causing cells, although some  emerging therapies may be more specific [22].  This has 
prompted the quest for antigen-specific treatments that solely target disease-causing antigen-
specific immune effector cells.  
 
4. Bone marrow and haematopoietic stem cell transplantation 
Bone marrow transplantation (BMT) has become widely used as a therapy for some 
haematological and solid tumours.  BMT or hematopoietic stem cell (HSC) transplantation 
(HSCT) is typically performed using a procedure where BM or HSC are harvested from an MHC 
non-identical donor (allogeneic) or the patient (autologous), patients are ‘conditioned’ and 
BM/HSC are infused (Figure 1).  For tumour therapy, high doses of radiation and/or 
chemotherapy are typically used to ensure maximum possible reduction of tumour burden and 
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allogeneic HSCT is used in order to capitalise on a strong graft vs leukemia or graft vs tumour 
effect in order to clear residual disease.  The conditioning used is also immuno- and myelo-
ablative thereby preventing immune rejection of transferred cells and facilitating engraftment of 
donor HSC.  BMT/HSCT is also used to treat genetic disorders such as sickle cell anemia, 
thalassemia and severe combined immunodeficiency disorder (SCID), where defects in the 
hematopoietic compartment are severely debilitating or life-threatening.  Conditioning regimens 
are similar to those used for allogeneic HSCT.  Allogeneic HSCT carries significant risk of 
GVHD which occurs in up to 60-80% of cases (30-40% of MHC-matched transplants) and leads 
to significant morbidity and mortality.  Clearly such a risk is acceptable only for the most serious 
or life-threatening illnesses.  Typically, approximately 2x10
6
 CD34
+
 cells/kg body weight is the 
minimum requirement for reliable engraftment.  Early in development of BMT procedures, whole 
BM was harvested but ‘mobilisation’ of HSC using granulocyte colony stimulating factor (G-
CSF) or G-CSF and cyclophosphamide is as effective, less invasive and is now widely used [23-
25].  Sufficient HSC can usually be harvested using a standard mobilisation regimen of 
10µg/kg/day G-CSF for 4 days prior to leukapheresis [25].   
 
5. Haematopoietic stem cell transplantation for autoimmune disease 
The principles developed for HSCT in tumour therapy or genetic deficiencies have been 
adapted for therapy of autoimmune disease.  It was reasoned that as myeloablative conditioning is 
also highly immuno-ablative it could be used to deplete disease-causing leukocytes and, after 
autologous HSC re-infusion for recovery of hematopoiesis, a new immune repertoire devoid of 
activated pathogenic specificities would develop [26].  An inherent component of this rationale is 
that, as the environmental trigger that elicited disease may have passed, autologous HSCT would 
facilitate an ‘immunological reset’ to alleviate or cure disease.  Preclinical studies with allogeneic 
BMT or BMT of BM expressing protective MHC alleles provided early evidence that complete 
resistance to disease could be achieved by full or mixed allogeneic chimerism [27, 28] and 
provided proof-of-principle that autoimmune diseases could be ‘cured’ from within the 
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hematopoietic compartment.  Although effective in animal models, allogeneic or mismatched 
HSCT remains a serious procedure with substantial risks so could only be considered for the most 
serious diseases.  Autologous HSCT, however, avoids GVHD and other risks associated with 
allogeneic or MHC-mismatched HSCT, making it more applicable to clinical use for autoimmune 
diseases.  Syngeneic and autologous HSCT was tested in animal models and found effective in 
EAE and experimental arthritis [29-31]. 
 
Between the initial pilot study in 1995 [32] and 2011, over 700 people with MS have 
undergone autologous HSCT [33].  Approximately 70% of treated patients remain free of disease 
progression 3 years post-transplant based on expanded disability status scale (EDSS) scores [34]. 
Autologous HSCT can be life-saving for patients with malignant MS [35] and is more effective in 
cases of relapsing-remitting MS than primary progressive disease [36, 37].  The potential of HSCT 
for refractory cases of RA was demonstrated in 1996 when a wheelchair bound patient received an 
autologous bone marrow transplant and demonstrated a subsequent reduction in Ritchie Articular 
Index (RAI) from 61 pre-transplant to just 7 at 6 months post-transplant [38].  Since then, a meta-
analysis of data from 15 centres where 76 RA patients were treated with autologous HSCT 
showed two-thirds of patients had positive outcomes but, unlike MS, responses were mostly 
transient with disease remission lasting 6 months to 2 years. Despite this, patients who were 
previously unresponsive to conventional disease modifying anti-rheumatic drugs (DMARDs) 
showed renewed sensitivity to treatment after relapse [39].  Autologous HSCT in SLE patients 
significantly reduces SLE disease activity index (SLEDAI) scores, complement C3 and C4 levels, 
antinuclear and anti double stranded DNA antibodies and increases renal function [40].  
Resolution of soft-tissue calcification has also been reported [41].  Interestingly, recent post-
transplant analyses have revealed CD8
+
 Treg are significantly increased in SLE patients post-
transplant and these are proposed to play a central role in restoration of tolerance post-transplant 
[42].  More recently, autologous HSCT has been tested in T1D and treatment of 15 recently-
diagnosed T1D patients showed encouraging results [43].  Pancreatic beta-cell function improved 
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in all but one patient as measured by C-peptide production and haemoglobin A1c.  Anti-GAD 
antibodies were reduced and insulin independence was maintained from 1 to 35 months.  
Continuation of the study culminated in a report on 23 patients, including long-term follow up of 
the 15 original patients and 20 of the 23 patients experienced insulin-free periods representing 
significant and prolonged disease amelioration [43].  No mortality was reported, however, several 
incidences of late-onset endocrine dysfunction were documented, including a case of Grave’s 
disease, autoimmune hypothyroidism, and transient hypergonadotrophic hypogonadism. 
Interestingly, preservation of islet beta-cell function is superior to that achieved with other, more 
conventional immunotherapies currently or recently trialled for T1D [44].   
 
Treatment related mortality (TRM) and other toxicities associated with the procedure remains a 
limiting factor for widespread application of HSCT as a routine treatment for autoimmune disease.  
G-CSF and Cy are associated with harmful side effects such as nausea, vomiting and hair loss and, 
interestingly, this is exacerbated in patients with autoimmune diseases.  A potentially serious 
complication is disease flare induced by G-CSF in MS, SLE , and RA [45, 46].  Conditioning 
regimes for HSCT aim to ablate or suppress the immune system prior to HSC-mediated immune 
recovery.  Myeloablative or non-myeloablative conditioning regimes can be utilised, with the 
difference lying in the intensity or dose of conditioning agents administered.  A direct association 
of conditioning intensity with the incidence of TRM was shown in a study of 473 patients with 
severe autoimmune disease carried out by the European Group for Blood and Marrow 
Transplantation (EBMT).  Patient selection has also been identified as a contributing factor to 
TRM [47].  The more advanced a patient’s disease, the higher the risk of a poor outcome. Some 
toxicities such as gut damage have been addressed with  increased use of non-myeloablative 
conditioning.  Progress in recent years has seen a significant decrease in TRM rates for clinical 
trials of all autoimmune diseases from 12% in 2001 to 5% in 2010 [48].   
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Despite the encouraging results obtained, significant risks and side effects along with a 
substantial relapse rate in some diseases must be addressed before autologous HSCT becomes 
more widely applicable.  Notwithstanding that low-intensity conditioning is associated with 
reduced risk of complications and mortality, HSCT is currently not a cure for autoimmune 
diseases and still represents a non-specific highly immune-ablative treatment.  Combinational 
approaches of HSCT with tolerance-inducing therapies may address the incidence of relapse and 
enable the widespread application of such a treatment. 
 
6. Combining HSCT and gene therapy to achieve better outcomes 
Although the potential of autologous HSCT for widespread application is currently restricted 
by transplant-related toxicities, the most significant impediment to high success rates in treated 
individuals is subsequent disease relapse.  Two underlying causes are most commonly proposed to 
underlie this, i) disease-causing leukocytes are not completely purged by pre-HSCT conditioning 
and ii) as autologous HSC are transplanted, the immune system is reinstated with the same 
complement of disease-associated genetic risks.  In the latter case, autologous HSCT relies solely 
on ‘resetting’ the immune system and contributes no ‘active’ tolerance mechanisms to limit 
disease recurrence depending on whether eliciting environmental influences are still present, the 
extent to which the disease is genetically-determined, and the influence of the pre-existing 
disease-associated inflammatory state in the recipient.  With these factors in mind, allogeneic 
HSCT may be more effective but is ethically unacceptable for all but the most serious conditions 
such as systemic sclerosis [49].  An alternative approach would be to somehow ‘modify’ HSC 
prior to re-infusion to ensure the presence of ‘active’ disease-inhibitory tolerance processes after 
HSCT.  It is conceivable that several approaches could be used that replace ‘susceptibility genes’ 
or engender (re-)instatement of antigen-specific tolerance to disease-causing autoantigens.  It is 
envisaged that the latter approach would purge or silence only disease-causing leukocytes while 
leaving the remainder of the immune system intact.  If exploited effectively, this could reduce 
toxicities and lead to more efficacious treatments. 
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Beginning in the 1990’s the importance of dendritic cells and other APC types in central and 
peripheral tolerance began to be recognised and DC were soon proposed as potential tools for 
limiting pathogenic T-cell responses [50].  In fact, it was shown that expression of the disease-
eliciting autoantigens H+/K+-ATPase or proinsulin targeted to APC could prevent development of 
autoimmune gastritis and autoimmune diabetes in relevant animal models [51, 52].  Since then it 
has been widely demonstrated that enforced expression of auto- or neo-antigens, expressed 
ubiquitously, leads to antigen-specific tolerance to the expressed antigen [53, 54].  A more 
focussed approach, however, is to genetically-target antigens to APC and extensive studies from 
our group and others [55, 56, 4] demonstrate the robustness of this approach.  In these settings, 
antigen-specific tolerance occurs through both central and peripheral tolerance pathways [57] 
including deletion, induction of unresponsiveness and Treg induction.  Whether tolerance 
mechanisms differ when antigen is targeted to APC is not clear but may be a moot point as 
ubiquitous expression also leads to expression in ‘tolerogenic’ APC.  Enforcing antigen 
expression in APC is sufficient to overcome inherent genetically-determined tolerance defects in 
autoimmune-prone mice [51, 52, 58, 59].  Capitalising on this knowledge, Steptoe and colleagues 
[60] progressed this approach when they demonstrated that transfer of ‘gene-engineered’ HSC 
encoding proinsulin transgenically-targeted to MHC class II APC completely prevented 
subsequent development of autoimmune diabetes in the spontaneously-diabetic NOD mouse.  This 
led to the proposal that HSC genetically-manipulated ex-vivo could form an effective ‘tolerogenic’ 
therapy for T-cell mediated autoimmune diseases in humans [60].  Similar to the demonstrations 
that highly-purified HSC could be used , bulk transgenic BM encoding H
+
/K
+
 ATPase was shown 
similarly to prevent autoimmune gastritis [61].  Unpublished studies from our laboratory have 
shown that BMT / HSCT from mice expressing APC-targeted antigen replicates in recipients the 
antigen-specific tolerance seen in donors thereby providing a mechanistic basis for concluding that 
disease prevention is achieved through induction of antigen-specific T-cell tolerance.  
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Transgenic ‘gene-engineered’ HSC can be used to explore therapeutic approaches in animal 
models, but for human application another approach must be used.  Fortuitously, development of 
retroviral and lentiviral vectors that could effectively transduce HSC paved the way for gene 
therapy employing HSC.  Subsequently, clinical trials have shown the effectiveness of this 
approach for overcoming genetic deficiencies that manifest within the hematopoietic compartment 
such as X-linked severe combined immunodeficiency (X-SCID) and adenosine deaminase (ADA) 
deficiency.  The technology used for such ‘restorative’ gene therapy can also be harnessed to 
target antigen expression to APC [62-64].  
 
Early studies investigating the use of HSC gene therapy for tolerance induction showed that 
BM engineered to encode alloantigen through retroviral transduction induced macrochimerism 
and allo-tolerance [65, 66].  Subsequently, transfer of BM transduced by viral vectors to encode 
autoantigens was found to prevent autoimmune disease development in a variety of animal 
models.  Xu and colleagues [67] showed that in conjunction with myeloablative irradiation, BM 
transduced to encode phospholipid protein (PLP) prevented induction of EAE by PLP 
immunisation.  Similarly, transduction of BM using retrovirus encoding either an 
immunodominant epitope of myelin oligodendrocytic glycoprotein (MOG) or whole MOG has 
been shown to lead to loss of T-cell responsiveness to the expressed determinant(s), prevention of 
anti-MOG antibody development and inhibition of EAE induction in response to immunisation 
with the encoded antigen [68, 69].  Overall, these studies using disease models elicited by specific 
antigens or antigen-specific TCR transgenic T cells show that induction of tolerance after antigen-
encoding BMT limits T-cell responses specific for the expressed protein or determinant(s) to 
prevent autoimmune disease elicited by immunisation with the targeted antigen.  
 
Autoimmune diseases are typically directed at a range of autoantigens.  The studies detailed 
above show that responsiveness to single disease-related autoantigens can be inhibited and HSCT 
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used to reinstate a repertoire tolerant to a single antigen.  They do not, however, address whether 
enforced expression of a single antigen protects from T-cell responses elicited by antigens other 
than that targeted for enforced expression.  In NOD mice, development of autoimmune diabetes 
occurs spontaneously without the need for immunisation against pancreatic β-cell antigens.  In this 
spontaneous disease, insulin appears to be the primary autoantigen to which diabetogenic T-cell 
responses are initiated and other T-cell responses against other -cell autoantigens are recruited by 
‘determinant spreading’ as disease progresses [59, 70].  In NOD mice, transgenic expression of 
proinsulin targeted to APC prevents development of responses to insulin, other -cell antigens and 
spontaneous diabetes [52, 58, 71].  Similarly, diabetes development is prevented by transfer of 
insulin-encoding HSC to young NOD mice [60] but not by transfer of non-engineered HSC.  In an 
extension of this approach, it was shown that BM transduced with a retroviral vector encoding 
proinsulin expressed under control of the endogenous viral LTR inhibited development of insulitis 
after transfer to young (3-4 week-old) female NOD mice when analysed 8 weeks later.  However, 
diabetes development was not assessed in these studies [72].  These NOD mouse studies provide 
bona-fide evidence that using ‘gene-engineered’ HSCT to induce ‘tolerance’ to a key autoantigen 
prevents the unfolding of a spontaneous disease where a highly diversified pathogenic repertoire is 
ultimately responsible for target tissue destruction.  While most studies have focussed primarily on 
T-cell responses, transfer of virally-transduced BM cells can also prevent antigen-specific 
antibody production in murine models [73, 74] and in non-human primates [75]  
 
An alternative approach to the induction of antigen-specific tolerance to disease-specific 
autoantigens could be to replace genetic alleles that promote disease susceptibility with those that 
provide a protective effect or to enforce expression of ‘protective’ genes.  One example of this 
approach might be to replace the ‘susceptibility’ variable N-terminal repeat (VNTR) of the insulin 
gene which drives low intrathymic expression of insulin and is associated with increased T1D 
incidence with the VNTR allele that drives higher expression of insulin and is associated with 
reduced T1D incidence.  However, an easier solution would be to enforcedly express (pro)insulin 
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in a tolerogenic fashion as described above.  In humans, T1D is tightly associated with inheritance 
of a ‘susceptibility’ allele of the MHC class II (HLA-DQ) β chain that lacks a charged amino acid 
at position 57 (β57-non Asp) [76].  While not the sole determinant of susceptibility, disease 
progression is increased by homozygosity for β57-non Asp alleles.  In NOD mice, I-Ag7 (the 
mouse homolog of the β57-non Asp HLA-DQB1) is required for diabetes development.  Congenic 
or transgenic expression of an alternative I-A β-chain or I-E (mouse homolog of HLA-DR which 
NOD do not normally express) prevents diabetes [77] through a mechanism that appears 
associated with altered T-cell selection [78].  Transfer of BM cells transduced to encode either 
β57-Asp containing I-Aβ-k or I-Aβ-d to young (5-6 wk-old) prediabetic NOD mice using 
myeloablative (1050 cGy) total body irradiation (TBI) subsequently prevents spontaneous diabetes 
development [79].  Reduced T-cell responses to islet antigens and increased negative selection of a 
diabetogenic T-cell specificity were demonstrated after transfer of BM encoding protective I-Aβ 
chains [79].  A potential drawback of this approach could be that an expressed, protective I-Aβ 
acts as the equivalent of an alloantigen and whether this approach would be safer than allogeneic 
HSCT in humans is unclear. Gene-therapy approaches using HSC could be supplemental to 
approaches aimed at local manipulation of autoimmune inflammation  [80, 81] 
 
Together the studies performed in EAE and diabetes models demonstrate that the immune 
system can readily be reset by HSCT using gene-engineered HSC and that reconstitution with a 
repertoire specifically tolerant to pathogenic autoantigen(s) prevents disease onset.  However, for 
clinical application, an approach to interrupt autoimmune disease progression is sought.  Attempts 
to inhibit disease progression in mouse models have met with mixed success.  When Xu et al used 
myeloablative irradiation (900cGy) conditioning they found transfer of PLP-encoding BM led to 
an approximately 50% reduction in the mean clinical score of PLP-induced EAE but efficacy was 
increasingly impaired as EAE progressed (12 days after disease onset) [67]. Chan and colleagues 
[68] used the same dose of irradiation but incorporated administration of depleting anti-CD4 
antibody after transfer of MOG-encoding BM and showed that disease progression was 
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interrupted and re-induction of disease by MOG immunisation prevented.  Together this suggests 
that during disease progression, immune ablation was required to permit reinstatement of a 
‘tolerant’ repertoire after HSCT and this provided an equivalent ‘preventative’ effect to that seen 
for HSCT prior to initial antigen priming.  Extending this, Tian and colleagues showed by using 
immune-depleting myeloablative TBI, that transfer of BM retrovirally transduced to encode 
protective β57-Asp-containing I-Aβ molecules abrogated recurrence of diabetes in NOD mice 
after syngeneic islet transplantation [82], again most likely trough a ‘preventative’ effect. In 
keeping with the possible requirement for immune ablation for effectiveness, non-myeloablative 
approaches to BMT using antigen-encoding BM are less efficacious that myeloablative 
approaches and as disease progresses the effectiveness of this approach appears to wane [67, 69]. 
 
The findings that antigen-encoding BMT/HSCT can induce ‘preventative’ tolerance and, when 
combined with immune ablation, prevent disease re-induction represent a substantial step forward 
for the potential of HSCT as a ‘cure’ for autoimmune diseases.  Incorporation of the ‘gene-
therapy’ steps required for ‘antigen-specific immunotherapy’ (‘tolerogenic HSCT’) could be 
readily incorporated into current HSCT practice with few additional risks, but with the profound 
potential to minimise or eliminate disease relapse.  This would achieve a distinct ‘active tolerance’ 
mechanism into the HSCT procedure to purge potentially pathogenic autoreactive T-cell 
repertoires thereby preventing the key immunological driver underlying disease relapse.  While 
studies to date indicate a high degree of potential for incorporation of ‘tolerogenic gene therapy’ 
into HSCT protocols, a number of hurdles that need to be the focus of current research efforts are 
still present. 
 
7. Challenges for moving forward with combined HSCT and gene therapy  
Studies of HSC-mediated ‘tolerogenic gene therapy’ in mouse models have primarily used 
myeloablative, immunoablative treatments or a combination of both to achieve engraftment of 
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transferred HSC and to ‘purge’ the repertoire of pre-existing pathogenic T-cells.  However, the 
long period required for a ‘new’ immune system ‘tolerant’ to the targeted (auto)-antigen(s) to be 
regenerated along with immune depletion has inherent drawbacks.  Not only is there an extended 
period of immune suppression but protective memory T-cell specificities such as those generated 
through immunisations are lost.  Thymic involution from adolescence onwards has also 
traditionally been considered an impediment to ‘full’ immune reconstitution of highly diverse T-
cell repertoires after immune ablation or HSCT in adults.  Recent evidence, however, suggests the 
thymus maintains more T-lymphopoietic activity than traditionally thought.  A more ideal 
approach, if possible, might be to exploit the inherent ability of ‘tolerogenic’ APC for peripheral 
tolerance induction to purge the T-cell repertoire of undesirable specificities.  In this scenario, 
development of autoantigen-expressing APC could silence pre-existing populations of 
autoantigen-specific T cells through one or more tolerance mechanisms such as deletion, induction 
of unresponsiveness or induction of Treg.  Successful exploitation of such an approach is yet to be 
demonstrated experimentally, but adoptive transfer studies performed by our laboratory [83, 84, 4] 
indicate possible success for such an approach.  If this proved possible, then theoretically, 
tolerance could be achieved using ‘gene-engineered’ HSCT in the absence of any immune 
ablation.  This is certainly the goal for antigen-specific immunotherapy and would dramatically 
extend the clinical utility of HSCT.   
 
Effector and memory T-cell responses develop early in the prodromal, or pre-clinical, phase of 
autoimmune diseases and typically, autoimmune diseases are identified only after such actively 
pathogenic effector and memory T-cell populations have become established.  In humans with 
T1D effector cells serve as a reliable predictor of disease progression [85, 86].  They continue to 
expand as disease progresses and ultimately form memory populations that persist in long-
standing diabetics [87, 88], long after β-cell function is lost.  Any ‘cure’ must therefore comprise 
an approach to terminate such pathogenic effector and memory T-cell responses either to permit 
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preservation of target tissues or to facilitate their regeneration or replacement.  Given that 
progression of some autoimmune diseases (e.g. T1D) to end-stage disease can be predicted, a 
‘window of therapeutic opportunity’ exists where interventions that terminate effector and 
memory T-cell responses could be employed to prevent further disease progression.  Herein lies 
the largest apparent hurdle for immunotherapy of autoimmune diseases.  Upon antigen 
stimulation, naïve T cells rapidly undergo terminal differentiation to effector and memory T cells.  
During this process naive Ag-specific T cells lose their highly malleable differentiation potential 
and become committed memory and effector populations. Compared to naive T cells, effector and 
memory T cells are more sensitive to antigen stimulation, exhibit faster response kinetics, reduced 
dependence on costimulation and can respond to lower affinity ligands.  Memory T cells may 
more resistant to induction of apoptosis than naive cells through increased expression of 
antiapoptotic molecules [89].  This fully differentiated nature and reduced requirement for 
costimulation has led to the belief that memory T-cells are resistant to inactivation or tolerance 
induction.  Indeed, memory T cells have been shown to provide a potent barrier to transplantation 
tolerance induction [90, 91] and may be resistant to regulation [92], conventional 
immunosuppression [88] and myeloablative conditioning regimens [93-96].  This is in line with 
observations that T cell ablation (e.g. anti-CD4) is required in addition to myeloablative 
conditioning to maximise the potential of antigen-encoding BM once disease has commenced [68, 
97].  Exciting new data from our laboratory has shown that, unexpectedly, effector and memory T 
cell responses can be effectively terminated when antigen is targeted to APC [98-100].  This 
suggests the possibility that gene-engineered HSCT might be useful for induction of antigen-
specific tolerance to pathogenic T-cell specificities even in established or progressing autoimmune 
diseases.  Such an outcome would give hope for the ultimate goal of an antigen-specific therapy 
where immune ablation is not necessary to eliminate pre-existing differentiated pathogenic 
effector and memory T-cells.  
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A major advantage of tolerogenic HSCT over other possible immunotherapeutic approaches is 
that once engrafted, ‘engineered’ HSC will continue to give rise to APC with enforced autoantigen 
expression.  Thus, as long as donor engraftment levels remain stable it may be possible to attain 
life-long tolerance due to the constant inactivation of any new autoreactive T-cells that develop.  
In fact, continued expression of the targeted antigen may be required to maintain tolerance 
induced by gene-engineered HSC [101], much in the same way it is required to maintain tolerance 
in transgenic mice [98].  Achievement of ‘life-long tolerance’ could be a distinct advantage of 
immunotherapy using gene-engineered HSC over other approaches where immunotherapeutic 
benefits can be transient.  
 
Experimental studies of tolerogenic HSCT in mouse models have employed almost exclusively 
non-targeted antigen expression, where ‘ubiquitous’ promoters drive expression in all cell types.   
It remains unclear whether ‘therapeutic’ autoantigen expression should be targeted to APC or if 
widespread expression under ubiquitous or endogenous viral promoters would be equally, or 
possibly, even more effective.  Based on mouse models, ‘targeting’ is not required to achieve 
tolerance and HSC engineered to encode ubiquitously-expressed antigens can lead to induction of 
tolerance in recipients e.g. [54].  Which APC, if any, might be most effective for induction of 
therapeutic tolerance is also poorly-defined.  Although DC clearly play an important role in 
maintaining T-cell tolerance they are primarily specialized for induction of immunity raising the 
question of whether other APC types may more effective tolerogens.  Evidence has existed for 
some time that, under certain conditions, B cells in particular, promote peripheral tolerance 
induction [102, 103] and more recent data has shown a role for B cells in peripheral inactivation of 
naïve CD8
+
 T cells [63] and possibly memory CD4
+
 T cells [104].  B cells have been effectively 
exploited for ‘engineered’ Ag expression and tolerance induction in many studies [105, 63].  We 
have shown ‘rapid inactivation’ of effector and memory CD8+ T cells when antigen is widely 
expressed through different APC types [99].  Alternatively, delivery of allo-antigen by transfer of 
T cells can effectively induce allo-tolerance [106].  In a single study using retrovirally-transduced 
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BM it was found that targeting MOG to CD11c
+
 cells somewhat reduced disease development, but 
the effect was not as profound as when MOG expression was controlled (i.e. ubiquitously 
expressed) by the endogenous retroviral LTR promoter [107]. 
 
Moving forward, there are other areas where additional research is required in order to 
understand how ‘gene-engineered’ HSC may be best applied as a clinically applicable therapeutic 
for autoimmune diseases.  For example, what level of engineered HSC engraftment (chimerism) is 
required for effective prevention or termination of T-cell responses or autoimmune disease?  We 
showed diabetes development in NOD mice was effectively inhibited by levels of proinsulin-
encoding HSC engraftment as low as 5% [60].  But, in general, most investigations have been 
performed using much higher levels of gene-engineered HSC-induced chimerism.  While low 
levels of chimerism are effective in ‘preventative’ approaches where myeloablative conditioning is 
used and a new ‘tolerant’ immune system is regenerated, whether such low levels would be 
effective when attempts are made to reduce the extent of myeloablation or immunoablation in 
experimental protocols is unclear.  It is readily apparent that the levels of ‘chimerism’ achievable 
in humans will be dependent on the nature of the ‘conditioning’ regime used.  As attempts are 
made to reduce the toxicity of conditioning will the dose of HSC transferred be sufficient and will 
the number of HSC required become a limiting factor?  Currently, conditioning-related toxicities 
are the biggest single challenge limiting widespread application of HSCT for autoimmune 
diseases. Current conditioning regimes, even ‘nonmyeloablative’ protocols are designed to be 
heavily immunoablative and further progress in development of conditioning regimes tailored to 
the needs of ‘tolerogenic’ HSCT is required.  For transduction of HSC, both retroviral and 
lentiviral vectors have proven effective in humans.  The ability of these vectors to integrate their 
genetic payload into the host genome is essential for their effectiveness but comes at a cost.  
Retroviruses may preferentially insert genetic material into oncogenic sites and the detrimental 
effects of this became apparent in a clinical trial for X-SCID where the therapeutic ‘gene’ was 
Coleman et al., Induction of antigen-specific tolerance ...  20 
 
inserted in close proximity to the proto-oncogene promoter LMO2, leading to leukemia in some 
recipients [108].  Lentiviral vectors may be safer in this respect [109] but concerns about 
recombination with ‘endogenous’ viruses have dogged attempts for clinical use.  A recent trial 
showed effectiveness of lentiviral vectors in ADA but further studies and follow-up will be 
required to fully define the comparative safety of each vector type.  Development of effective 
alternative approaches for gene transfer, such as non-viral vectors, while most likely some way off 
would broaden the clinical utility of HSCT for autoimmune diseases.   
 
8. Summary 
Autoimmune diseases afflict a large percentage of the world’s population and are both 
debilitating and life-long.  To date, there is no ‘cure’ for any autoimmune disease and current 
treatments are riddled with serious side-effects.  HSCT has emerged as a potential treatment for a 
number of autoimmune diseases, but is limited by treatment related toxicities and a high incidence 
of disease relapse in some settings.  A promising way forward is to combine ‘tolerogenic’ gene 
therapies with autologous HSCT to provide active tolerance mechanisms and induced permanent 
disease remission.  This approach has the potential to prevent disease relapse, minimise the need 
for immunoablative conditioning and diversify the application of autologous HSCT-based 
immunotherapies.  Further understanding of how to optimise gene delivery and autoantigen 
expression will add impetus to application of progress of ‘tolerogenic’ HSCT.  We suggest that 
targeting autoantigen expression to ‘tolerogenic’ APC, such as dendritic cells, will provide 
significant therapeutic benefit and has the potential to antigen-specifically turn-off established 
pathogenic T-cell responses underlying some autoimmune diseases.  This could mark a new era 
for treatment of immunological disorders especially autoimmune diseases. 
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Take Home Messages 
 Nonmyeloablative conditioning reduces the transplant-related risks of HSCT but 
preserves host immunity 
 Clinical trials treating AD with nonmyeloablative HSCT have significant relapse rates  
 Remaining or re-emerging autoreactive cells need to be dealt with for permanent 
disease remission 
 Gene therapy has been used successfully in humans and may be feasibly combined 
with HSCT to antigen- specifically silence pathogenic autoreactive T-cells  
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Figure 1 
1. Mobilisation 
HSC are mobilised from the bone 
marrow to the blood by 
administering granulocyte-colony 
stimulating factor (G-CSF) with or 
without cyclophosphamide (Cy).   
2. Harvest 
HSC are harvested from the blood by 
apheresis.  The patient’s blood is 
passed through a machine to select 
HSC and the remaining cells are 
returned to the patient.   
3. Storage 
Collected HSC are cryopreserved 
awaiting transduction and 
conditioning of the patient.   
4. Conditioning 
The patient is conditioned to deplete 
disease-causing immune cells and 
create ‘space’ in the bone marrow 
for the infused HSC.  Various 
conditioning regimens can be used 
such as busulfan, cyclophosphamide 
or irradiation.  
5. Transduction and transplantation 
HSC are thawed and transduced with a 
vector encoding autoantigen(s) appropriate 
to the patient’s autoimmune disease.  
Transduced HSC are infused into the 
patient.  HSC travel to and engraft in the 
bone marrow where they give rise to cells 
expressing autoantigen(s).   
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Figure 1.   A ‘conceptualised’ scenario for ‘tolerogenic’ autologous HSCT.  Hematopoietic 
stem cells (HSC) are harvested using administration of mobilising agents and apharesis.  HSC are 
then stored, then recovered and transduced with a vector encoding appropriate autoantigen(s).  
Patients undergo mild conditioning before infusion of ‘engineered’HSC.  Once engrafted in the 
bone marrow, infused HSC give rise to cells expressing autoantigen(s).  The specific cells that 
express the autoantigens could be determined by choice of the promoter/antigen construct encoded 
in the transducing vector.   
 
